Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer

Randomized Multicenter Phase II Study Evaluating Two Dosing Schedules of TG4010(MVA-MUC1-IL2) in Patients With Adenocarcinoma of the Prostate

NCT00040170CI-TRIAL-00000495terminatedPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Prostatic Neoplasms	Prostate Neoplasm	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
MVA-MUC1-IL2	Biological	—	UNRESOLVED

Eligibility

Eligibility (as posted)

Sex: Male
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* Rising PSA after surgery or radiation for prostate cancer

Exclusion Criteria:

* Metastasis or local disease
* Prior hormone treatment

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: May 1, 2002
Primary completion: —
Completion: —
First posted: Jun 25, 2002
Last update posted: Nov 2, 2006
Enrollment: 50
Lead sponsor: Transgene INDUSTRY
Collaborators: University of California, Los Angeles; The Cleveland Clinic; University of Arizona
Keywords: Adenocarcinoma of the prostate

Data updated 22 days agoSource updated Nov 2, 2006source: clinicaltrials

Locations

Locations by country (3)

Country	Sites	Recruiting
United States	3	0

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.